Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
PCProcessa Pharmaceuticals, Inc. logo

Processa Pharmaceuticals, Inc. (PCSA)

NASDAQ Capital Market · Currency in USD
$1.81 ▼ -0.05 (-2.69%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.81 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$1.86
Open
$1.76
Day's Range
$1.75 – $1.90
52 Week Range
$1.04 – $10.85
Volume
35,045
Avg. Volume
210,062
Market Cap
$5.06M
Beta (5Y Monthly)
0.97
PE Ratio (TTM)
--
EPS (TTM)
-$4.89
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$225.00

Profile: Processa Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
12
CEO
George K. Ng

Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate -$1.00
DateEst.Actual
Aug 14, 2026-$1.00-$1.19Miss
May 7, 2026-$1.00-$1.29Miss
Mar 19, 2026-$1.50-$18.50Miss
Nov 6, 2025-$2.00-$1.75Beat
Aug 7, 2025-$5.75-$6.25Miss
May 8, 2025-$19.25-$7.50Beat

Analyst view

Consensus price target
$225.00 ▲ +12,330.9%
Range $225.00 – $225.00
Rating: Buy
Buy 80% · Hold 20% · Sell 0%

Get free alerts on PCSA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.